Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Disease Attributes: later-stage trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Disease Attributes: 3 US clinical trials tracked, none currently recruiting.
Disease Attributes is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is University of Colorado, Denver, running 3 of these trials.
Enrollment posture brief
Registry condition disease-attributes
OPEN 0 | RECR 0% | LATE 2 | EARLY 0 | RANK #5209 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Disease Attributes has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Disease Attributes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Disease Attributes is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients
University of Colorado, Denver
NCT04534959
Strategy to Avoid Excessive Oxygen in Major Burn Patients
University of Colorado, Denver
NCT04534972
Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration Intervention
University of Colorado, Denver
NCT06374225
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Disease Attributes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Disease Attributes trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Disease Attributes page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Disease Attributes trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- University of Colorado, Denver sponsors the most Disease Attributes trials on record, review their full trial history before evaluating a specific study. See University of Colorado, Denver's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Disease Attributes condition card totals 3 registered trials; most-linked intervention Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg); top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.